本文選題：胰島素降解酶 + 胰島素抵抗��； 參考：《東南大學(xué)》2017年博士論文

【摘要】：第一部分 IDE與胰島素抵抗和糖尿病MCI的相關(guān)性研究背景:胰島素降解酶(IDE)可降解胰島素和β-淀粉樣蛋白(Aβ),與2型糖尿病慢性并發(fā)癥及(AD)的發(fā)生發(fā)展有密切的關(guān)系。胰島素抵抗(IR)是2型糖尿病的始發(fā)因素之一,既往研究表明IR會(huì)增加認(rèn)知功能障礙甚至AD的發(fā)生風(fēng)險(xiǎn),也是糖尿病輕度認(rèn)知障礙(MCI)向AD轉(zhuǎn)化的危險(xiǎn)因素。目的:研究IDE與胰島素抵抗、2型糖尿病MCI的相關(guān)關(guān)系,探討IDE對(duì)2型糖尿病MCI發(fā)生的預(yù)測(cè)價(jià)值。方法:本研究共招募239位2型糖尿病患者,根據(jù)MoCA得分將其分為MCI組和認(rèn)知功能正常組。所有受試者入組后于次日早晨7點(diǎn)空腹抽取靜脈血,測(cè)定空腹血糖、空腹C肽、糖化血紅蛋白、肝腎功能、血脂全套,計(jì)算胰島素抵抗指數(shù)(HOMA-IR)。用多維度量表評(píng)估受試者的認(rèn)知功能,用聚合酶鏈?zhǔn)椒磻?yīng)-限制性片段長度多態(tài)性法檢測(cè)IDE rs4646958基因多態(tài)性,并用酶聯(lián)免疫吸附法測(cè)定血清IDE濃度。結(jié)果:納入的2型糖尿病患者中,132人符合MCI的診斷標(biāo)準(zhǔn),107人是與之相匹配的認(rèn)知功能正常組。結(jié)果表明:1、與認(rèn)知功能正常組比較,2型糖尿病MCI組患者的血清IDE顯著降低(P0.001),HOMA-IR顯著升高(P0.001); 2、在2型糖尿病MCI患者中,血清IDE水平和MoCA得分呈顯著正相關(guān)(r = 0.827;P0.001 ),HOMA-IR和MoCA得分呈顯著負(fù)相關(guān)(r = -0.644;P0.001); 3、在所有2型糖尿病患者中做的相關(guān)分析表明,血清 IDE 水平和 MoCA 得分(r = 0.798;P 0.001)呈正相關(guān),和 HOMA-IR (r =-0.586;P 0.001 )、連線試驗(yàn) A (r =-0.464;P 0.001 )、連線試驗(yàn) B (r = -0.399;P 0.001)、空腹血糖(r = -0.409;P0.001)、糖化血紅蛋白(r = -0.237;P= 0.015)及平均血糖波動(dòng)幅度(r =-0.502;P 0.001)呈負(fù)相關(guān);4、回歸分析顯示,調(diào)整了年齡、性別、受教育年限、肝腎功能和血脂水平后,IDE(P=0.001)、糖化血紅蛋白(P=0.024)、空腹C肽(P0.001)是2型糖尿病發(fā)生MCI的影響因素;5、IDE rs4646958基因型在2型糖尿病認(rèn)知障礙組及認(rèn)知功能正常組均未發(fā)現(xiàn)統(tǒng)計(jì)學(xué)差異。結(jié)論:IDE參與胰島素抵抗相關(guān)的2型糖尿病早期認(rèn)知功能障礙(特別是執(zhí)行功能),可能成為早期的預(yù)測(cè)指標(biāo)。IDE rs4646958基因多態(tài)性在2型糖尿病認(rèn)知障礙中并未發(fā)現(xiàn)顯著統(tǒng)計(jì)學(xué)結(jié)果,需要大規(guī)模樣本進(jìn)一步明確其在易感人群中的預(yù)測(cè)價(jià)值。第二部分 IDE參與KKAy小鼠認(rèn)知功能障礙的機(jī)制及PPARy激動(dòng)劑的干預(yù)效應(yīng)背景:胰島素抵抗是2型糖尿病的最顯著的臨床病理特征,早于顯著的2型糖尿病癥狀發(fā)生,參與了糖尿病早期認(rèn)知障礙的發(fā)生以及向AD的轉(zhuǎn)化。過氧化物酶增殖物活化受體γ(PPARγ)的表達(dá)和胰島素的敏感性呈正相關(guān),它可以通過調(diào)節(jié)胰島素信號(hào)通路,調(diào)控IDE的表達(dá)。PPARy激動(dòng)劑可改善胰島素抵,減少認(rèn)知功能障礙和AD的發(fā)生。我們前期的研究發(fā)現(xiàn)2型糖尿病MCI的患者中,血清IDE水平較低,和胰島素抵抗介導(dǎo)的認(rèn)知功能下降顯著相關(guān),可能是2型糖尿病發(fā)生認(rèn)知障礙的預(yù)測(cè)指標(biāo)。在臨床研究的基礎(chǔ)上,我們進(jìn)一步通過動(dòng)物實(shí)驗(yàn)來證實(shí)IDE參與胰島素抵抗相關(guān)的認(rèn)知障礙機(jī)制和PPARy激動(dòng)劑的預(yù)防和干預(yù)效應(yīng)。目的:從動(dòng)物水平上探討IDE保護(hù)動(dòng)物認(rèn)知功能的可能機(jī)制及其與Aβ水平的相關(guān)性,以及PPARγ激動(dòng)劑在胰島素抵抗介導(dǎo)的2型糖尿病小鼠認(rèn)知功能損傷的預(yù)防和治療效果。方法:本研究采用高脂喂養(yǎng)KKAy小鼠作為2型糖尿病輕度認(rèn)知功能障礙模型,羅格列酮作為PPARy激動(dòng)劑對(duì)小鼠進(jìn)行預(yù)防和干預(yù)。選取6周齡清潔級(jí)健康雄性KKAy小鼠和其對(duì)應(yīng)的C57BL/6j (C57)小鼠(均購于中國醫(yī)學(xué)科學(xué)院實(shí)驗(yàn)動(dòng)物所),適應(yīng)性喂養(yǎng)一周。其中隨機(jī)選出三組KKAy小鼠在8周齡時(shí)分別給予低、中、高劑量羅格列酮預(yù)防,其他三組在小鼠15周齡出現(xiàn)認(rèn)知障礙時(shí)給予羅格列酮低、中、高劑量干預(yù),還有一組作為2型糖尿病未干預(yù)的對(duì)照組。將羅格列酮溶于0.9%生理鹽水中配置成所需濃度的混懸液,低劑量組每天予1mg/ (kg·d)灌胃,中劑量組每天予3.3mg/ (kg d)灌胃,高劑量組每天予10mg/ (kg· d)灌胃,糖尿病對(duì)照組及正常組C57小鼠予等劑量生理鹽水灌胃3個(gè)月。處理后進(jìn)行以下檢測(cè):1、每周監(jiān)測(cè)小鼠體質(zhì)量、空腹血糖及空腹胰島素水平,計(jì)算出相關(guān)的胰島素抵抗指數(shù);2、通過水迷宮及避暗實(shí)驗(yàn)觀察小鼠的行為學(xué)變化;3、Western及RT-PCR法測(cè)定小鼠海馬PPARγ、IDE的mRNA及蛋白水平;4、對(duì)腦組織切片進(jìn)行HE染色、尼氏染色,鏡下觀察各組小鼠大腦組織神經(jīng)元形態(tài)、尼氏體的改變;5、免疫化學(xué)法測(cè)定小鼠腦組織PPARγ、IDE、Aβ的表達(dá)。結(jié)果:1、各組小鼠體質(zhì)量、空腹血糖、胰島素和胰島素抵抗指數(shù)水平的比較:各周齡KKAy小鼠的體質(zhì)量、空腹血糖、胰島素及胰島素抵抗水平均高于對(duì)照組C57小鼠(P 0.05),和模型對(duì)照組相比,羅格列酮預(yù)防和干預(yù)組的體質(zhì)量均無顯著統(tǒng)計(jì)學(xué)差異(P0.05),空腹血糖、胰島素及胰島素抵抗水平顯著下降(P0.05),高劑量效果更為顯著。2、各組小鼠行為學(xué)比較:水迷宮實(shí)驗(yàn)結(jié)果表明,與正常對(duì)照組相比,模型對(duì)照組小鼠逃避潛伏期顯著延長,穿臺(tái)次數(shù)顯著減少(P0.05);與模型對(duì)照組小鼠相比,羅格列酮干預(yù)和預(yù)防組小鼠逃避潛伏期顯著減少,穿臺(tái)次數(shù)顯著延長(P0.05)。避暗實(shí)驗(yàn)結(jié)果表明,和正常對(duì)照組小鼠相比,模型組小鼠避暗潛伏期顯著縮短,錯(cuò)誤次數(shù)顯著增加(P0.05),羅格列酮低預(yù)防和干預(yù)后,潛伏期和錯(cuò)誤次數(shù)均有顯著改善(P0.05),高劑量的效果尤其顯著。3、海馬組織PPARγ及IDE的mRNA及蛋白水平:模型對(duì)照組小鼠海馬內(nèi)PPARy及IDE的mRNA及蛋白水平顯著下降(P0.05),經(jīng)羅格列酮預(yù)防和干預(yù)后PPARy及IDE的mRNA及蛋白水平均顯著增加(P 0.05),高劑量的效果尤其顯著。4、各組小鼠神經(jīng)元形態(tài)的改變:HE染色:正常對(duì)照組小鼠海馬組織中,神經(jīng)元細(xì)胞形態(tài)結(jié)構(gòu)未見顯著異常,細(xì)胞核形狀呈圓形,細(xì)胞結(jié)構(gòu)層次清楚且排列整齊。模型對(duì)照組小鼠海馬組織的部分細(xì)胞出現(xiàn)形態(tài)結(jié)構(gòu)的破壞,細(xì)胞核皺縮,邊緣模糊,細(xì)胞結(jié)構(gòu)排列松散,有變形甚至壞死。羅格列酮預(yù)防和干預(yù)后,小鼠海馬組織的細(xì)胞形態(tài)結(jié)構(gòu)的破壞程度有所減輕,排列松散情況好轉(zhuǎn),神經(jīng)元的變性壞死程度減輕,病理損傷有所好轉(zhuǎn)。尼氏染色:正常對(duì)照組小鼠海馬神經(jīng)元未見顯著異常,胞核膜和核仁較清楚;模型對(duì)照組小鼠的海馬、額葉皮質(zhì)的細(xì)胞排列疏散、細(xì)胞間隙較寬,胞漿內(nèi)Nissl體較少。羅格列酮預(yù)防和干預(yù)組小鼠與模型組小鼠比較,組織結(jié)構(gòu)有所改善,神經(jīng)元細(xì)胞排列密集、整齊,胞漿中Nissl體增加。5、免疫化學(xué)法測(cè)定小鼠腦組織PPARγ、IDE、Aβ的表達(dá):正常組小鼠海馬組織細(xì)胞排列緊密,胞體小,Aβ蛋白著色較淺,表達(dá)較弱。模型對(duì)照組小鼠海馬組織細(xì)胞排列疏松,胞體較大,Aβ著色深,表達(dá)呈強(qiáng)陽性,PpAaγ及IDE的IOD值顯著減少(P0.05)。羅格列酮預(yù)防和干預(yù)組小鼠PPARy及IDE的IOD值顯著增加,Aβ蛋白顯著減少(P0.05)。結(jié)論:IDE參與胰島素抵抗所致的糖尿病早期認(rèn)知障礙,對(duì)認(rèn)知功能起到保護(hù)作用。PPARγ激動(dòng)劑可能是通過升高IDE和降低Aβ水平來預(yù)防和改善KKAy小鼠的認(rèn)知功能障礙的。第三部分 IDE介導(dǎo)的PPARy激動(dòng)劑對(duì)PC12細(xì)胞APP和Aβ的影響背景:前期實(shí)驗(yàn)證實(shí)PPARγ激動(dòng)劑可能是通過升高IDE和降低Aβ水平來預(yù)防和改善KKAy小鼠的認(rèn)知功能障礙的。但在細(xì)胞水平,PPARy激動(dòng)劑對(duì)神經(jīng)細(xì)胞的保護(hù)作用機(jī)制尚未明確。目的:研究IDE介導(dǎo)的PPARγ激動(dòng)劑對(duì)PC12細(xì)胞淀粉樣前體蛋白(APP)和Aβ的影響,探討PPARy激動(dòng)劑神經(jīng)保護(hù)作用可能的潛在機(jī)制。方法:選取未分化的PC12細(xì)胞株,以神經(jīng)生長因子誘導(dǎo)為神經(jīng)元細(xì)胞。預(yù)試驗(yàn)采用1Oμmol/L的羅格列酮、20μmol/L的氯喹、12.5μmol/L的T0070907分別處理后,處理組和對(duì)照組相比具有顯著的統(tǒng)計(jì)學(xué)差異,后續(xù)的實(shí)驗(yàn)就用該濃度作為理想濃度來處理PC12細(xì)胞。在細(xì)胞穩(wěn)定生長24小時(shí)后隨機(jī)分為六組:正常對(duì)照組、羅格列酮干預(yù)組、T0070907處理組、T0070907預(yù)處理+羅格列酮組、氯喹處理組、氯喹預(yù)處理+羅格列酮組,每個(gè)組設(shè)6個(gè)平行復(fù)孔。干預(yù)處理后收集各組相應(yīng)時(shí)間點(diǎn)的細(xì)胞,用RT-PCR以及Western blotting分別檢測(cè)PPARγ、IDE、APP等指標(biāo)mRNA和蛋白的表達(dá)水平;用ELISA法檢測(cè)細(xì)胞培養(yǎng)液上清液Aβ水平。結(jié)果:結(jié)果顯示:1、和正常對(duì)照組相比,羅格列酮干預(yù)組的PPARy和IDE的mRNA和蛋白含量顯著增加(P 0.05),APP的mRNA和蛋白含量顯著減少(P0.05); 2、單獨(dú)用T0070907處理組和用T0070907與羅格列酮聯(lián)合處理組相比,PPARγ、IDE和APP的mRNA和蛋白含量未見顯著統(tǒng)計(jì)學(xué)差異(P0.05); 3、和氯喹處理組相比,用氯喹與羅格列酮聯(lián)合處理組PPARy的mRNA和蛋白含量顯著升高,IDE和APP的mRNA和蛋白含量未見顯著統(tǒng)計(jì)學(xué)差異(P 0.05); 4、和正常對(duì)照組相比,羅格列酮干預(yù)組的PPARy和IDE的培養(yǎng)液上清液的Aβ含量顯著減少(P0.05),其他各組培養(yǎng)液上清液的Aβ含量未見顯著統(tǒng)計(jì)學(xué)差異(P0.05)。結(jié)論:PPARy激動(dòng)劑可誘導(dǎo)DDE的表達(dá),從而促進(jìn)APP和Aβ的降解。但是,PPARy激動(dòng)劑對(duì)IDE誘導(dǎo)的神經(jīng)細(xì)胞損傷的保護(hù)作用,均可被PPARy抑制劑T0070907及IDE抑制劑氯喹所拮抗,表明PPARγ激動(dòng)劑的神經(jīng)細(xì)胞損傷的保護(hù)機(jī)制是通過PPARy激活I(lǐng)DE途徑參與調(diào)節(jié)的。
[Abstract]:The first part of the study on the correlation between IDE and insulin resistance and diabetes MCI: insulin degrading enzyme (IDE) degrading insulin and beta amyloid (A beta) is closely related to the development of chronic complications of type 2 diabetes and (AD). Insulin resistance (IR) is one of the initiation factors of type 2 diabetes. Previous studies have shown that IR will increase. The risk of cognitive dysfunction or even AD is also a risk factor for mild cognitive impairment of diabetes (MCI) to AD. Objective: To study the correlation between IDE and insulin resistance and MCI in type 2 diabetes, and to explore the predictive value of IDE for the occurrence of MCI in type 2 diabetes. Methods: a total of 239 patients with type 2 diabetes were recruited and the score of MoCA was based on the score of MoCA. It was divided into the MCI group and the normal cognitive function group. All the subjects took the venous blood at 7 a. m. on the next morning and measured the fasting blood glucose, fasting C peptide, glycosylated hemoglobin, liver and kidney function, blood lipid whole set, and calculated the insulin resistance index (HOMA-IR). The cognitive function of the subjects was evaluated by the multidimensional scale and the polymerase chain reaction restriction was used. The polymorphism of IDE rs4646958 gene was detected by sex fragment length polymorphism and serum IDE concentration was measured by ELISA. Results: among the patients with type 2 diabetes, 132 were in accordance with the diagnostic criteria of MCI and 107 were matched with the normal cognitive function group. The results showed that: 1, compared with the normal cognitive function group, the MCI group of type 2 diabetes mellitus was developed. Serum IDE was significantly decreased (P0.001) and HOMA-IR significantly increased (P0.001); 2, in type 2 diabetic MCI patients, serum IDE levels were positively correlated with MoCA scores (r = 0.827; P0.001), and HOMA-IR and MoCA scores were negatively correlated (r =;); 3, in all patients with type 2 diabetes, serum levels and levels MoCA score (r = 0.798; P 0.001) was positive correlation, and HOMA-IR (R =-0.586; P 0.001), connection test A (R =-0.464; P 0.001), connection test B (0.001), fasting blood glucose, glycated hemoglobin (0.015) and average blood glucose fluctuations (0.001) negative correlation; 4, regression analysis showed After adjusting age, sex, years of education, liver and kidney function and blood lipid levels, IDE (P=0.001), glycosylated hemoglobin (P=0.024), and fasting C peptide (P0.001) were the factors affecting MCI in type 2 diabetes; 5, IDE rs4646958 genotypes were not found in the cognitive impairment group of type 2 diabetes and the normal cognitive function group. Conclusion: IDE participates in the pancreas. The early cognitive impairment (especially executive function) of type 2 diabetes associated with Isle resistance may be an early predictor of the.IDE rs4646958 gene polymorphism in the cognitive impairment of type 2 diabetes, which requires a large sample to further clarify its predictive value in the susceptible population. Second part IDE The mechanism of participation in cognitive dysfunction in KKAy mice and the intervention effect of PPARy agonists: insulin resistance is the most significant clinicopathological feature of type 2 diabetes, earlier than the onset of type 2 diabetes, the occurrence of early cognitive impairment in diabetes and the conversion to AD. The peroxidase proliferator activated receptor gamma (PPAR gamma) ) expression is positively related to insulin sensitivity, and it can regulate the insulin signaling pathway by regulating the expression of IDE.PPARy agonists to improve insulin resistance and reduce the occurrence of cognitive dysfunction and AD. Our previous study found that in patients with type 2 diabetes MCI, the level of IDE in blood albumin was lower and the cognitive work mediated by insulin resistance was found in patients with type 2 diabetes. Reduced significant correlation, may be a predictor of cognitive impairment in type 2 diabetes. On the basis of clinical studies, we further confirmed the mechanism of cognitive impairment associated with insulin resistance and the prevention and intervention effects of PPARy agonists by IDE. Objective: To explore the cognitive function of IDE protection from animal levels. The possible mechanisms and their correlation with A beta levels, as well as the preventive and therapeutic effects of PPAR gamma agonists on cognitive impairment in type 2 diabetic mice induced by insulin resistance. Methods: This study used high fat feeding KKAy mice as a mild cognitive impairment model of type 2 diabetes, and rosiglitazone was used as a PPARy agonist to mice. Prevention and intervention. Select 6 week old clean healthy male KKAy mice and their corresponding C57BL/6j (C57) mice (all purchased in the laboratory animal Institute of Chinese Academy of Medical Sciences) for one week. Among them, three groups of KKAy mice were randomly selected to be given low, medium and high dose rosiglitazone at 8 weeks of age, and the other three groups were identified at 15 weeks of age. A low, medium and high dose intervention was given to rosiglitazone, and a group of untreated type 2 diabetes was given as a control group. Rosiglitazone was dissolved in 0.9% physiological saline to form a desired concentration of suspension. The low dose group was given 1mg/ (kg. D) every day. The medium dose group was given 3.3mg/ (kg d) every day, and the high dose group was given 10mg/ (kg. D) every day. Gavage, the diabetic control group and the normal group C57 mice were given the same dose of normal saline for 3 months. After treatment, the following tests were performed: 1, the body mass, fasting blood glucose and fasting insulin level were monitored weekly, and the related insulin resistance index was calculated; 2, the behavior changes of mice were observed by water maze and dark experiment; 3, Western and RT-PC were observed. The R method was used to determine the PPAR gamma, mRNA and protein levels of IDE in the hippocampus of mice. 4, the brain tissue sections were stained with HE, Nissl staining, and the changes of neuron morphology and Nissl body were observed under the microscope. 5, the expression of PPAR gamma, IDE, and A beta in the brain tissue of mice was measured by immunochemistry. Results: 1, the mass of mice in each group, fasting blood glucose, insulin and islets of insulin and islet. Comparison of the level of vegetal resistance index: body mass, fasting blood glucose, insulin and insulin resistance at all weeks of age of KKAy mice were higher than that of C57 mice in the control group (P 0.05). Compared with the model control group, there was no significant difference in body mass between the prophylaxis and intervention groups (P0.05), fasting blood glucose, insulin and insulin resistance levels were significant. Decrease (P0.05), high dose effect is more significant.2, mice Behavior Comparison in each group: water maze test results show that compared with the normal control group, the escape latency of the model control group was significantly prolonged, and the number of wear stage decreased significantly (P0.05), compared with the model control group, the incubation period of rosiglitazone intervention and prevention group was significantly reduced. The test results showed that the dark latency of the mice in the model group was significantly shortened and the number of errors increased significantly (P0.05) compared with the normal control group, and the latency and error times of rosiglitazone were significantly improved (P0.05), and the effect of high dose was particularly significant (.3, PPA), PPA in the hippocampus, and PPA in the hippocampus. The level of mRNA and protein of R gamma and IDE: the mRNA and protein levels of PPARy and IDE in the hippocampus of the model control group decreased significantly (P0.05). The mRNA and protein levels of PPARy and IDE increased significantly after the prophylaxis and intervention of rosiglitazone (P 0.05). In the hippocampus of the mice, the morphological structure of the neurons was not remarkable, the nucleus shape was round, the structure of the cell was clear and orderly. The part of the hippocampus tissue in the model control group was damaged by the morphological structure, the nucleus crinkled, the edge was blurred, the cell structure was loosely arranged, and the rosiglitazone was deformed and even necrotic. Prevention and prognosis, the damage degree of cell morphology and structure in the hippocampus of mice was reduced, loosely arranged, the degree of degeneration and necrosis of neurons reduced and pathological damage improved. Nissl staining: no significant abnormalities were found in the hippocampus neurons in normal control group, and the cell nuclear membrane and nucleolus were clearer; the hippocampus of model control mice In the frontal cortex, the cells in the frontal cortex were arranged to evacuate, the cell space was wide and the Nissl body in the cytoplasm was less. The tissue structure of the mice in the rosiglitazone prevention and intervention group was better than the model mice, the cells were arranged densely and neatly, the Nissl body in the cytoplasm increased.5. The expression of PPAR gamma, IDE and A beta in the brain tissue of the mice was measured by immunochemistry: the normal group was small. The cells in the hippocampus of the rat were arranged closely, the cell body was small, the expression of A beta protein was shallow, and the expression was weak. The cells in the hippocampus of the model control group were loosely arranged, the cell body was large, the expression of A beta was strong positive, the IOD value of PpAa gamma and IDE decreased significantly (P0.05). The IOD value of PPARy and IDE in the mice of rosiglitazone prevention and intervention group was significantly increased, A beta protein showed significant. Reduction (P0.05). Conclusion: IDE participates in the early cognitive impairment induced by insulin resistance. The protective effect of.PPAR gamma agonist on cognitive function may be to prevent and improve the cognitive impairment of KKAy mice by increasing IDE and reducing A beta. The effect of PPARy agonists on PC12 cell APP and A beta in the third part of IDE Background: earlier experiments confirmed that PPAR gamma agonists could prevent and improve the cognitive impairment of KKAy mice by raising IDE and reducing A beta levels. But at the cellular level, the mechanism of the protective action of PPARy agonists on the nerve cells is not clear. Objective: To study the IDE mediated PPAR gamma agonist on the amyloid precursor protein (APP) of PC12 cells (APP) and to the IDE mediated PPAR gamma agonist. The effects of A beta on the potential mechanism of the neuroprotective effect of PPARy agonists. Methods: an undifferentiated PC12 cell line was selected to be induced by nerve growth factor as neuron cell. The pretreatment was treated with 1O mu mol/L rosiglitazone, chloroquine 20 mu mol/L, and T0070907 of 12.5 mu mol/L respectively. The treatment group was significantly more than the control group. PC12 cells were treated with the concentration as ideal concentration. After 24 hours of stable growth, the cells were randomly divided into six groups: the normal control group, the rosiglitazone intervention group, the T0070907 treatment group, the T0070907 preconditioning + rosiglitazone group, the chloroquine treatment group, the chloroquine preconditioning + rosiglitazone group, each group of 6 parallel compounds. RT-PCR and Western blotting were used to detect the expression level of mRNA and protein of PPAR gamma, IDE, APP and so on, and the level of A beta in the supernatant of cell culture liquid was detected with ELISA method. Results: 1, the PPARy and IDE mRNA and eggs of the rosiglitazone intervention group were compared with the normal control group. The white content increased significantly (P 0.05), and the content of mRNA and protein in APP decreased significantly (P0.05). 2, there was no significant difference in the mRNA and protein content of PPAR gamma, IDE and APP (P0.05) compared with the T0070907 treatment group and the combination of T0070907 and rosiglitazone combined treatment group. 3, chloroquine and rosiglitazone were treated with chloroquine and rosiglitazone in combination with the chloroquine treatment group. The content of mRNA and protein in Y increased significantly. The mRNA and protein content of IDE and APP had no significant statistical difference (P 0.05). 4, the content of A beta in the supernatant of the culture liquid of rosiglitazone intervention group decreased significantly compared with the normal control group (P0.05), and no significant statistical difference was found in the A beta content of the supernatant of other groups (P0.05). On the other hand, PPARy agonists can induce the expression of DDE and promote the degradation of APP and A beta. However, the protective effect of PPARy agonists on IDE induced neuronal damage can be antagonized by the PPARy inhibitor T0070907 and chloroquine, a IDE inhibitor, indicating that the protective mechanism of the PPAR gamma agonist's nerve cell damage is to participate in the modulation by PPARy activation IDE pathway. The festival.

【學(xué)位授予單位】：東南大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2017
【分類號(hào)】：R587.2

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 張惠,張建,蘇昕,王廷濤,陳厚芹;胰島素抵抗與妊娠高血壓綜合征的關(guān)系[J];華北煤炭醫(yī)學(xué)院學(xué)報(bào);2000年04期

2 傅誠強(qiáng);胰島素抵抗和擇期性手術(shù)[J];國外醫(yī)學(xué).外科學(xué)分冊(cè);2001年03期

3 賈偉平;中國人群胰島素抵抗的狀況[J];國外醫(yī)學(xué).內(nèi)分泌學(xué)分冊(cè);2002年04期

4 寧光;李長貴;洪潔;湯正義;李果;龔艷春;彭怡文;郭冀珍;沈衛(wèi)峰;商淑華;羅邦堯;陳家倫;;胰島素抵抗基礎(chǔ)和臨床研究[J];醫(yī)學(xué)研究通訊;2002年11期

5 姚小皓,沈凱,李學(xué)軍;胰島素對(duì)中樞神經(jīng)系統(tǒng)疾病的影響[J];生理科學(xué)進(jìn)展;2003年01期

6 柯紅林;;2型糖尿病中胰島素抵抗發(fā)生機(jī)制的研究進(jìn)展[J];國外醫(yī)學(xué)(老年醫(yī)學(xué)分冊(cè));2003年03期

7 常桂娟;胰島素抵抗的環(huán)境因素[J];現(xiàn)代診斷與治療;2004年02期

8 米杰 ,張力;胰島素抵抗[J];中華預(yù)防醫(yī)學(xué)雜志;2004年04期

9 王繼旺,張素華,任偉,杜娟,陳靜,包柄楠,汪志紅,苗青;吸煙與胰島素抵抗的相關(guān)性調(diào)查與分析[J];中國公共衛(wèi)生;2004年08期

10 陽柳雪;劉紅;;可溶性腫瘤壞死因子受體2與胰島素抵抗[J];中國醫(yī)學(xué)文摘.內(nèi)科學(xué);2004年01期

相關(guān)會(huì)議論文 前10條

1 陳艷秋;宗敏;華莉;李臻;肖菲;孫建琴;;2型糖尿病患者肝臟脂肪與胰島素抵抗的關(guān)系[A];中國營養(yǎng)學(xué)會(huì)老年?duì)I養(yǎng)分會(huì)第七次全國營養(yǎng)學(xué)術(shù)交流會(huì)“營養(yǎng)與成功老齡化”暨國家級(jí)繼續(xù)教育項(xiàng)目“神經(jīng)系統(tǒng)疾病醫(yī)學(xué)營養(yǎng)治療”資料匯編[C];2010年

2 陳艷秋;陳敏;宗敏;華莉;李臻;張?chǎng)我?孫建琴;;2型糖尿病患者肝臟脂肪分布與胰島素抵抗[A];老年?duì)I養(yǎng)研究進(jìn)展與老年?duì)I養(yǎng)供餐規(guī)范研討會(huì)暨糖尿病腎病醫(yī)學(xué)營養(yǎng)治療進(jìn)展學(xué)習(xí)班資料匯編[C];2011年

3 宋曉敏;耿秀琴;郭長磊;;胰島素抵抗幾個(gè)相關(guān)因素在公安人群中的狀態(tài)與分析[A];中華醫(yī)學(xué)會(huì)第六次全國內(nèi)分泌學(xué)術(shù)會(huì)議論文匯編[C];2001年

4 游捷;陳瑤;黃培基;林哲章;;血清可溶性腫瘤壞死因子受體與胰島素抵抗的關(guān)系[A];中華醫(yī)學(xué)會(huì)第六次全國內(nèi)分泌學(xué)術(shù)會(huì)議論文匯編[C];2001年

5 謝彬;陳上云;郭堅(jiān);劉薇;勞干誠;;監(jiān)測(cè)真胰島素觀察胰島素抵抗與胰島素敏感性[A];中華醫(yī)學(xué)會(huì)第六次全國內(nèi)分泌學(xué)術(shù)會(huì)議論文匯編[C];2001年

6 尹義輝;王經(jīng)武;;消胰抗治療胰島素抵抗的臨床研究[A];第七次全國中醫(yī)糖尿病學(xué)術(shù)大會(huì)論文匯編[C];2003年

7 呂圭源;劉賽月;;中藥抗胰島素抵抗研究進(jìn)展[A];浙江省2005年中藥學(xué)術(shù)年會(huì)論文集[C];2005年

8 王曉靜;劉正齊;;一種簡便實(shí)用且較準(zhǔn)確評(píng)估胰島素抵抗的新方法[A];全國中西醫(yī)結(jié)合內(nèi)分泌代謝病學(xué)術(shù)會(huì)議論文匯編[C];2006年

9 白秀平;李宏亮;楊文英;肖建中;王冰;杜瑞琴;樓大鈞;;脂肪分存順序與肝臟及肌肉胰島素抵抗的關(guān)系[A];2006年中華醫(yī)學(xué)會(huì)糖尿病分會(huì)第十次全國糖尿病學(xué)術(shù)會(huì)議論文集[C];2006年

10 孫勤;李伶;楊剛毅;歐陽凌云;陳渝;劉華;唐毅;Gunther Boden;;小鼠擴(kuò)展胰島素鉗夾術(shù)的建立[A];2006年中華醫(yī)學(xué)會(huì)糖尿病分會(huì)第十次全國糖尿病學(xué)術(shù)會(huì)議論文集[C];2006年

相關(guān)重要報(bào)紙文章 前10條

1 ;胰島素小常識(shí)[N];保健時(shí)報(bào);2004年

2 ;胰島素抵抗，怎么辦？[N];解放日?qǐng)?bào);2004年

3 中南大學(xué)湘雅二醫(yī)院老年病科副教授 陳化;什么是“胰島素抵抗”[N];健康報(bào);2001年

4 張家慶 （教授）;適度鍛煉身體改善胰島素抵抗[N];上海中醫(yī)藥報(bào);2003年

5 本報(bào)記者 韓曉英;注射胰島素會(huì)成癮嗎[N];中國中醫(yī)藥報(bào);2002年

6 張怡梅 劉 斌;惡性腫瘤與胰島素抵抗[N];中國中醫(yī)藥報(bào);2003年

7 健康時(shí)報(bào)特約記者 陳錦屏;胖人易發(fā)“胰島素抵抗”[N];健康時(shí)報(bào);2007年

8 殳雪怡;胰島素抵抗 有辦法“抵抗”嗎[N];家庭醫(yī)生報(bào);2007年

9 劉文山;胰島素抵抗[N];家庭醫(yī)生報(bào);2007年

10 孟懷東;“致命四重奏”與胰島素抵抗[N];中國醫(yī)藥報(bào);2007年

相關(guān)博士學(xué)位論文 前10條

1 孫潔;胰島素降解酶介導(dǎo)胰島素抵抗所致2型糖尿病輕度認(rèn)知功能障礙的機(jī)制研究[D];東南大學(xué);2017年

2 殷青青;胰島素抵抗大鼠腦組織損傷機(jī)制以及番茄紅素的保護(hù)作用研究[D];山東大學(xué);2015年

3 施琳穎;二氫楊梅素通過誘導(dǎo)細(xì)胞自噬改善骨骼肌胰島素抵抗的作用及其機(jī)制研究[D];第三軍醫(yī)大學(xué);2015年

4 隆敏;下丘腦室旁核神經(jīng)肽Y長期過表達(dá)誘導(dǎo)外周胰島素抵抗作用機(jī)制研究[D];第三軍醫(yī)大學(xué);2015年

5 黃文輝;高胰島素抑制腎臟尿酸排泄的基礎(chǔ)與臨床研究以及氯沙坦的干預(yù)機(jī)制[D];蘭州大學(xué);2015年

6 付鋒;缺血后心肌胰島素抵抗促發(fā)缺血性心力衰竭及其機(jī)制[D];第四軍醫(yī)大學(xué);2015年

7 王宗保;NO-1886對(duì)糖脂代謝的影響及機(jī)制研究[D];南華大學(xué);2014年

8 張真穩(wěn);小檗堿協(xié)同甘丙肽降低2型糖尿病鼠脂肪組織胰島素抵抗的實(shí)驗(yàn)研究[D];揚(yáng)州大學(xué);2015年

9 何奕多;TNF-α對(duì)脂聯(lián)素多聚化修飾及分泌調(diào)控的研究[D];華中農(nóng)業(yè)大學(xué);2015年

10 陳璇;白虎二地湯調(diào)控胰島素信號(hào)通路改善2型糖尿病胰島素抵抗的研究[D];南京中醫(yī)藥大學(xué);2015年

相關(guān)碩士學(xué)位論文 前10條

1 宋衛(wèi)衛(wèi);阻塞性睡眠呼吸暫停低通氣綜合征胰島素抵抗的相關(guān)因素研究[D];鄭州大學(xué);2017年

2 李晨;辛伐他汀、胰島素聯(lián)合用藥對(duì)糖尿病大鼠下頜骨骨折愈合的影響[D];河北聯(lián)合大學(xué);2014年

3 賈曉嬌;血清Vaspin、u樗�、脂联素灾R焉鍰悄蠆』頰咧興郊?jí)坞淫o核氐摯溝墓叵礫D];河北醫(yī)科大學(xué);2015年

4 黃聲;胰島素抵抗與認(rèn)知功能障礙的關(guān)系研究[D];福建醫(yī)科大學(xué);2015年

5 牛尚梅;骨骼肌PGC-1α在高脂導(dǎo)致的胰島素抵抗中的作用機(jī)制[D];河北醫(yī)科大學(xué);2015年

6 安雨;血清視黃醇結(jié)合蛋白-4與2型糖尿病及肥胖的相關(guān)性研究[D];河北醫(yī)科大學(xué);2015年

7 陳旭;高胰島素水平導(dǎo)致肥胖相關(guān)機(jī)制研究[D];鄭州大學(xué);2015年

8 劉晨曦;津力達(dá)改善棕櫚酸誘導(dǎo)的肌細(xì)胞胰島素抵抗的機(jī)制[D];河北醫(yī)科大學(xué);2015年

9 段力園;津力達(dá)顆粒對(duì)高脂誘導(dǎo)的HepG2細(xì)胞胰島素抵抗影響的研究[D];河北醫(yī)科大學(xué);2015年

10 張東蛟;津力達(dá)對(duì)高脂誘導(dǎo)的胰島素抵抗ApoE基因敲除小鼠脂肪組織中脂代謝的影響[D];河北醫(yī)科大學(xué);2015年

，

本文編號(hào)：1778284